ATE354565T1
Hydroxyethylamine derivatives for the treatment of alzheimer's disease
Abstract
The present invention relates to novel hydroxyethylamine compounds having Asp2 (beta-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated beta-amyloid levels or beta-amyloid deposits, particularly Alzheimer's disease.
Term
Term ended
Projected expiry passed 3 December 2023, 2.8 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
1 priority claim, no other members on record
Priority claims1
| Document | Office | Kind | Date |
|---|---|---|---|
| 0228410 | United Kingdom | A |
2 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Ceased due to non-payment of the annual feeCeasedREN | REN | |
| Publication of translation of european patent specificationUEP | UEP |
Numbers
- Application
- 3767756
Titles2
- German
- HYDROXYETHYLAMIN-DERIVATE FÜR DIE BEHANDLUNG VON ALZHEIMER
- English
- HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER
Classification
- CPC, 14
- C07D207/267
- C07D207/26
- C07D211/76
- C07D275/02
- C07D279/02
- C07D401/12
- C07D403/12
- C07D405/12
- C07D409/12
- C07D417/12
- A61P25/00
- A61P25/28
- A61P43/00
- C07D275/03
- IPC, 11
- A61P25 28
- C07D207 26
- C07D207 267
- C07D211 76
- C07D275 02
- C07D279 02
- C07D401 12
- C07D403 12
- C07D405 12
- C07D409 12
- C07D417 12